This study aims to comprehensively evaluate the association between using the newer classes of hypoglycemic agents—SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors—and their risk of developing DKA in patients with T2D. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.